{"id":8618,"date":"2022-05-20T15:40:43","date_gmt":"2022-05-20T14:40:43","guid":{"rendered":"https:\/\/healthinnovationnenc.org.uk\/?page_id=8618"},"modified":"2024-02-23T14:18:36","modified_gmt":"2024-02-23T14:18:36","slug":"inclisiran","status":"publish","type":"page","link":"https:\/\/healthinnovationnenc.org.uk\/what-we-do\/improving-population-health\/cardiovascular-disease-prevention\/lipid-management-pathway\/inclisiran\/","title":{"rendered":"Inclisiran"},"content":{"rendered":"

Health Innovation Networks<\/a> are the delivery partners for the deployment of the novel therapy Inclisiran in England.<\/p>\n

Inclisiran bridges a gap in the Lipid Management\u00a0Pathway<\/a>, and provides a new treatment option for patients who have had a Cardiovascular Disease (CVD) event and are not responding to maximally tolerated statins or medications such as PCSK9 inhibitors<\/a>, ezetimibe and bempedoic acid.<\/p>\n

HI NENC is delivering this programme within the North East and North Cumbria.<\/p>\n

Background <\/strong><\/h3>\n

Inclisiran is an innovative new treatment for people at risk of Cardiovascular Disease, which has been made available to patients more quickly thanks to the first NHS population health agreement<\/a> between NHS England and NHS Improvement, the Health Innovation Network and the pharmaceutical company, Novartis.<\/p>\n

This three-way collaboration will increase the treatment options available to this patient cohort and is an example of a new method of scaling an approved innovation in a way that accelerates patient access and improves patient outcomes.<\/p>\n

Roll out of Inclisiran in primary care<\/strong><\/h3>\n

In September 2021, Inclisiran gained NICE approval, recommending the drug for people with high cholesterol who have already had a previous cardiovascular event to reduce their low-density lipoprotein (LDL) cholesterol. The new drug can be given to patients in primary care as a twice-yearly injection.<\/p>\n

HI NENC is working closely with clinicians in the region to support them with the introduction of Inclisiran into local lipid management pathways. This will involve providing primary care teams with information, education and training to help teams to prescribe the most appropriate treatment for patients.<\/p>\n

As the rollout of new treatments is not usually undertaken on a national scale, there is currently inequitable access across the country to novel treatments. This additional element of the Lipids Management and FH programme will help address inequalities by enabling all eligible patients to easily access the treatment via their GP practice.<\/p>\n

Inclisiran trials \u2013 demonstrating patient outcomes <\/strong><\/h3>\n

Inclisiran, a first-in-class small interfering RNA therapy, received a licence from the European Commission in December 2020 following the results of a robust clinical development programme.<\/p>\n

The drug removes harmful LDL cholesterol (LDL-c) from the blood and in three studies across over 3,700 patients is proven to reduce LDL-c by 50% by using RNA interference (RNAi) to boost the liver\u2019s ability to remove it from the blood.<\/p>\n

High levels of LDL-c suggests that people are more likely to suffer a heart attack or stroke. Sustained lowering of LDL-c has been shown to help prevent the development and progression of Atherosclerotic Cardiovascular Disease (ASCVD), a potentially serious condition. It is caused by a build-up of cholesterol in the blood vessels, known as plaque, and causes narrowing and restriction of blood flow to and from the heart and other vital organs, increasing the risk of heart attack and stroke.<\/p>\n

Indication of inclisiran<\/strong><\/h3>\n

Inclisiran is an LDL-c lowering therapy that, with two maintenance doses a year (following an initial dose and a follow-up dose at 3 months), delivers effective and sustained LDL-c\u00a0reduction. \"\"<\/a><\/p>\n

Inclisiran is indicated in adults for secondary prevention with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet:<\/p>\n